Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Company Ltd (OP: ESALF )

55.05 UNCHANGED
Streaming Delayed Price Updated: 10:35 AM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 55.05
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 55.05
Today's Range 55.05 - 55.05
52wk Range 43.19 - 76.96
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
 
Via Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
 
Via Benzinga

Performance

YTD
-9.01%
-9.01%
1 Month
+0.09%
+0.09%
3 Month
-9.01%
-9.01%
6 Month
-12.34%
-12.34%
1 Year
+18.37%
+18.37%

More News

Read More
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
Via Benzinga
The 7 Best Growth Stocks to Buy for February 2023
Via InvestorPlace
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
Via Benzinga
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
Via Benzinga
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
Via Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
Via Benzinga
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
Via Benzinga
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Via Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
Via Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
Via Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Via Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
Via Benzinga
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
Via Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
Via Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
Via Benzinga
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
Via Benzinga
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer
Via Benzinga
Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting
Via Benzinga
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
Via Benzinga
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
Via Benzinga
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.